Skip to main content
    N

    Nektar Therapeutics (NKTR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $36.44
    -0.83 (-2.23%)

    Market Cap: $1.27B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Nektar Therapeutics (NKTR) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Nektar Therapeutics (NKTR) trades at 23.9x sales and 1.5x book value. Its P/S of 23.9x is above its 5-year median of 4.7x. Its forward P/E is 34.0x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E34.0x
    Price to sales23.9x
    Price to book1.5x
    PEGN/A
    FCF yield-20.7%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 54.2% above 15.5x and its P/B is 54.5% below 3.3x.

    MultipleCurrent5-year median10-year median
    P/S23.9x4.7x15.5x
    P/B1.5x2.4x3.3x
    Medians of month-end values through Oct 2026: 57 to 60 months (5-year) and 112 to 113 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 1.2x in 2023 to 40.8x in 2017.

    Year endPriceP/EP/SP/B
    2025$42.28N/A13.1x9.6x
    2024$13.94N/A2.0x3.3x
    2023$8.47N/A1.2x0.8x
    2022$33.88N/A4.6x1.2x
    2021$202.55N/A24.3x3.7x
    2020$254.87N/A28.8x2.8x
    2019$323.69N/A33.0x2.7x
    2018$492.808.0x4.7x3.3x
    2017$895.35N/A40.8x111.0x
    2016$183.96N/A10.3x20.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    Frequently Asked Questions About NKTR

    What is NKTR's forward P/E ratio?

    Nektar Therapeutics has a forward P/E ratio of 34.0x.

    What is NKTR's price to sales ratio?

    Nektar Therapeutics has a price to sales ratio of 23.9x.